Reported Earnings • May 27
Full year 2025 earnings: Revenues exceed analyst expectations Full year 2025 results: Revenue: €210.5m (up 90% from FY 2024). Net loss: €29.6m (loss widened 159% from FY 2024). Revenue exceeded analyst estimates by 15%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Diversified Financial industry in Germany. Price Target Changed • May 08
Price target decreased by 8.2% to €45.00 Down from €49.00, the current price target is an average from 2 analysts. New target price is 45% above last closing price of €30.95. Stock is down 13% over the past year. The company is forecast to post a net loss per share of €0.69 next year compared to a net loss per share of €0.50 last year. New Risk • Apr 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (8.6% average weekly change). New Risk • Apr 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Major Estimate Revision • Oct 18
Consensus EPS estimates fall by 188% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€0.24 to -€0.69 per share. Revenue forecast of €157.7m unchanged since last update. Diversified Financial industry in Germany expected to see average net income growth of 75% next year. Consensus price target of €48.00 unchanged from last update. Share price was steady at €38.00 over the past week. Reported Earnings • Oct 15
First half 2025 earnings released: €0.69 loss per share (vs €0.23 loss in 1H 2024) First half 2025 results: €0.69 loss per share (further deteriorated from €0.23 loss in 1H 2024). Revenue: €71.0m (up 42% from 1H 2024). Net loss: €16.1m (loss widened 259% from 1H 2024). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Diversified Financial industry in Germany. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 46% per year, which means it is well ahead of earnings. Major Estimate Revision • Sep 11
Consensus EPS estimates fall by 118% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €166.0m to €157.7m. Losses expected to increase from €0.11 per share to €0.24. Diversified Financial industry in Germany expected to see average net income growth of 50% next year. Consensus price target down from €49.00 to €48.00. Share price fell 7.8% to €34.30 over the past week. Major Estimate Revision • Aug 19
Consensus revenue estimates increase by 12%, EPS downgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from €148.1m to €166.0m. EPS expected loss of €0.11 per share, down from profit of €1.12 per share previously. Diversified Financial industry in Germany expected to see average net income growth of 86% next year. Consensus price target of €49.00 unchanged from last update. Share price was steady at €41.10 over the past week. New Risk • Jul 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Shareholders have been diluted in the past year (29% increase in shares outstanding). Duyuru • Jun 02
CHAPTERS Group AG, Annual General Meeting, Jul 09, 2025 CHAPTERS Group AG, Annual General Meeting, Jul 09, 2025, at 14:00 W. Europe Standard Time. Reported Earnings • Jun 02
Full year 2024 earnings: Revenues in line with analyst expectations Full year 2024 results: Revenue: €119.1m (up 68% from FY 2023). Net loss: €11.5m (loss widened 181% from FY 2023). Revenue was in line with analyst estimates. Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Diversified Financial industry in Germany. Price Target Changed • May 23
Price target increased by 44% to €49.00 Up from €34.00, the current price target is provided by 1 analyst. New target price is 21% above last closing price of €40.60. Stock is up 71% over the past year. The company is forecast to post earnings per share of €0.37 next year compared to a net loss per share of €0.23 last year. Duyuru • May 23
Expatrio Global Services GmbH agreed to acquire Fintiba GmbH from CHAPTERS Group AG (XTRA:CHG). Expatrio Global Services GmbH agreed to acquire Fintiba GmbH from CHAPTERS Group AG (XTRA:CHG) on May 22, 2025. Bastian Krieghoff, CEO of Fintiba, will be appointed to the Executive Board of CHAPTERS Group AG by the Supervisory Board.
The transaction is subject to the usual contractual conditions is expected to close in May 2025. New Risk • May 06
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Price Target Changed • Feb 12
Price target increased by 26% to €34.00 Up from €27.00, the current price target is provided by 1 analyst. New target price is 8.3% above last closing price of €31.40. Stock is up 75% over the past year. The company is forecast to post earnings per share of €0.36 next year compared to a net loss per share of €0.23 last year. New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 39% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Reported Earnings • Oct 23
First half 2024 earnings released: €0.23 loss per share (vs €0.18 loss in 1H 2023) First half 2024 results: €0.23 loss per share (further deteriorated from €0.18 loss in 1H 2023). Revenue: €50.0m (up 49% from 1H 2023). Net loss: €4.48m (loss widened 49% from 1H 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Diversified Financial industry in Germany. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 39% per year, which means it is well ahead of earnings. Duyuru • Oct 18
CHAPTERS Group AG (XTRA:CHG) acquired Xplain AG. CHAPTERS Group AG (XTRA:CHG) acquired Xplain AG on October 18, 2024. Xplain includes the two companies Xplain AG and the Spanish development partner Xplain Ibérica. Both will continue to operate independently, as Andreas Löwinger, CEO of Xplain AG, told the Keystone-SDA news agency. The total of 60 employees of both companies will keep their jobs. All projects will also be continued. Löwinger will remain CEO until a successor is found.
CHAPTERS Group AG (XTRA:CHG) completed the acquisition of Xplain AG on October 18, 2024. New Risk • Jun 06
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 10.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Shareholders have been diluted in the past year (10.0% increase in shares outstanding). Duyuru • Jun 05
CHAPTERS Group AG, Annual General Meeting, Jul 09, 2024 CHAPTERS Group AG, Annual General Meeting, Jul 09, 2024, at 14:00 W. Europe Standard Time. Reported Earnings • May 28
Full year 2023 earnings released Full year 2023 results: Revenue: €78.3m (up 86% from FY 2022). Net loss: €4.08m (loss narrowed 38% from FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. New Risk • Apr 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (10.0% increase in shares outstanding). Price Target Changed • Mar 15
Price target increased by 14% to €24.00 Up from €21.00, the current price target is provided by 1 analyst. New target price is 18% above last closing price of €20.40. Stock is up 67% over the past year. The company is forecast to post earnings per share of €0.09 next year compared to a net loss per share of €0.41 last year. Duyuru • Mar 07
CHAPTERS Group AG, Annual General Meeting, Jul 09, 2024 CHAPTERS Group AG, Annual General Meeting, Jul 09, 2024. Reported Earnings • Oct 05
First half 2023 earnings released: €0.25 loss per share (vs €0.035 profit in 1H 2022) First half 2023 results: €0.25 loss per share (down from €0.035 profit in 1H 2022). Revenue: €33.7m (up 77% from 1H 2022). Net loss: €4.20m (down €4.72m from profit in 1H 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 49% per year whereas the company’s share price has increased by 44% per year. New Risk • Oct 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Shareholders have been diluted in the past year (10.0% increase in shares outstanding). New Risk • Sep 04
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Duyuru • Dec 14
MEDIQON Group AG announced that it has received funding MEDIQON Group AG announced that a private placement of successfully completion of the capital increase on December 12, 2022. Reported Earnings • May 30
Full year 2021 earnings released: €0.21 loss per share (vs €0.68 loss in FY 2020) Full year 2021 results: €0.21 loss per share (up from €0.68 loss in FY 2020). Revenue: €28.7m (up €27.6m from FY 2020). Net loss: €2.27m (flat on FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance. Reported Earnings • Sep 22
First half 2021 earnings released First half 2021 results: Net income: €15.7k (up €29.8k from 1H 2020). Reported Earnings • Jun 29
Full year 2020 earnings released Full year 2020 results: Net loss: €2.27m (loss narrowed 55% from FY 2019). Is New 90 Day High Low • Feb 12
New 90-day high: €5.40 The company is up 11% from its price of €4.88 on 13 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 5.0% over the same period. Is New 90 Day High Low • Jan 27
New 90-day low: €4.24 The company is down 9.0% from its price of €4.64 on 28 October 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 11% over the same period. Is New 90 Day High Low • Oct 01
New 90-day low: €4.74 The company is down 18% from its price of €5.80 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 9.0% over the same period.